Compare MMLP & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | ECOR |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 100.3M |
| IPO Year | 2002 | 2018 |
| Metric | MMLP | ECOR |
|---|---|---|
| Price | $2.18 | $10.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.17 |
| AVG Volume (30 Days) | 9.3K | ★ 74.1K |
| Earning Date | 10-14-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $32,032,000.00 |
| Revenue This Year | N/A | $30.85 |
| Revenue Next Year | N/A | $29.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.65 | ★ 27.20 |
| 52 Week Low | $1.89 | $4.41 |
| 52 Week High | $3.27 | $12.70 |
| Indicator | MMLP | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | N/A |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.42 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 45.45 | 0.00 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.